Bristol Myers Squibb (BMY)
Bristol Myers Squibb (BMY) product encyclopedia
Milk powder: well-known Mead Johnson brand It is a brand of Bristol Myers Squibb (Already in February 2017 Lijieshi Acquisition) -
Wound care: Kangfubao brand, its main products include stoma, wound treatment products, skin and wound care products. -
Medical equipment: bone correction&bone formation products, etc. -
Drugs: cardiovascular drugs, anticancer drugs, central nervous drugs, etc. are the most famous. For example, Jinshierkang, Shierkang and Weikangfu of Jinshierkang series; Isovue brand anti delusional drug, Lipostat ester anti hypertension. -
Non prescription health care products: Gerber brand infant health care equipment and other nutritional vitamin products, painkillers, skin drugs, etc. -
Cosmetics , bodybuilding products and household products: including well-known Miss clairol, Utless and Condition hair products, Sea Brand skin products, Vanish dishwashing agent, etc.
Bristol Myers Squibb (BMY) main pharmaceutical products:
-
Avalide (irbesartan/hydrochlorothiazide) - and Sanofi Joint Sales -
Avapro (irbesartan) - and Sanofi Joint Sales -
Coumadin (warfarin) -
Eliquis (apixaban) - and Pfizer Joint Sales -
Plavix (clopidogrel) - and Sanofi Joint Sales -
Pravachol (pravastatin)
-
Bydureon (exenatide extended-release) -
Byetta (exenatide) -
Glucophage (metformin) - BMS is only sold in USA -
Glucophage XR (metformin extended release) - BMS is only sold in USA -
Glucovance (glyburide/methaformin) - BMS is only sold in USA -
Kombiglyze XR/Kombiglyze (saxagliptin/metformin extended release) - and AstraZeneca Joint marketing -
Onglyza (saxagliptin) - and AstraZeneca Joint marketing
-
Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) - and Gilead Sciences Joint Marketing -
Azactam (aztreonam) -
Baraclude (entecavir) -
Daklinza (daclatasvir) -
Evotaz (atazanavir/cobicistat) -
Megace (megestrol acetate) -
Reyataz (atazanavir) -
Sustiva/Stocrin (efavirenz) -
Videx (didanosine) -
Video EC (didanosine sustained-release) -
Zerit (stavudine)
-
Kenalog-10 (triamcinolone acetonide) -
Kenalog-40 (triamcinolone acetonide)
-
BiCNU (carmustine) -
CeeNU (lomustine) -
Droxia/Hydrea (hydroxycarbamide) -
Empliciti (Elotuzumab) -
Erbitux (cetuximab) -
Etopophos (etoposide) -
Ixempra (ixabepilone) -
Lysodren (mitotane) -
Megace (megestrol acetate) -
Opdivo (nivolumab) -
Sprycel (dasatinib) -
Taxol (paclitaxel) -
Vumon (teniposide) -
Yervoy (ipilimumab)
-
Abilify (aripiprazole) - and Japan Otsuka Pharmaceutical (Otsuka Corporation, TYO: 4578) Joint Marketing
-
Orencia (abatacept)
-
Nulojix (belatacept)
Bristol Myers Squibb (BMY) Historical Encyclopedia
-
In 1887, William McLaren Bristol and John Ripley Myers founded the Clinton Pharmaceutical Company in Clinton, New York, which is the predecessor of Bristol Myers Squibb -
In 1898, it was renamed Bristol, Myers Company -
In 1900, the company was registered as a joint-stock subsidiary and turned its business focus to the wholesale and retail of drugs -
In 1924, the company's products were sold to 26 countries -
In 1929, the company's shares were listed in New York -
In 1943, the company acquired Cheplin Laboratories and produced penicillin and antibiotics in large quantities for the allied forces. -
In 1959, it acquired Clairol, a wig manufacturer. -
In 1965, it acquired the household product manufacturer Drackett -
In 1972, Zimmer Manufacturing, a surgical products company, was acquired -
In 1978, it acquired Unitek, a dental product manufacturer -
From 1974 to 1980, the company had 11 new anti-cancer drugs on the market, bringing profits of 200 million dollars to the company -
In 1986, the company merged with Biotechnology Enterprise Gene Systems Corporation (GSC). During this period, the company also achieved a prominent market position in the treatment and control of AIDS.
-
In 1856, Dr. Edward Robinson Squibb founded Squibb in Brooklyn, New York, to produce pure ether -
In 1905, Squibb's son sold the company to Merck Founder Theodore Wick. -
From 1909 to 1929, the company's annual sales jumped from 414000 dollars to 130 million dollars. -
During World War II, the company became a major supplier of morphine and penicillin. -
In 1946, the company expanded to Latin America, Europe and other places, and set up manufacturers in Mexico, Italy and Argentina. -
In 1971, the company was renamed Squibb Co., Ltd. -
In 1975, the annual sales reached 1 billion dollars.
-
In 1989, Bristol Myers and Squibb, two major pharmaceutical manufacturers in the United States, merged to form the current Bristol Myers Squibb -
In 1990, Bristol Myers Squibb Pharmaceutical Research Institute was founded in Princeton -
In 1991, the National Cancer Research Association authorized Bristol Myers Squibb to develop new anti-cancer drugs -
December 29, 1992, BMY research results - TAXOL ®， Approved by the US Food and Drug Administration (FDA) -
In 1993, Bristol Myers Squibb TAXOL was patented and put into production -
In 2007, Bristol Myers Squibb acquired Adnexus Therapeutics -
Bristol Myers Squibb Medical Imaging, a division of Bristol Myers Squibb, was sold to Avista Capital Partners in 2007 -
In 2008, BMS sold its ConvaTec to Avista Capital Partners&Nordic Capital Fund VII -
In 2008, Bristol Myers Squibb acquired Kosan Biosciences -
In 2009, Bristol Myers Squibb acquired Medarex -
In 2009, Bristol Myers Squibb was stripped Mead Johnson 。 On February 11, 2009, Mead Johnson was in the United States New York stock exchange Listed, share code MJN. Mead Johnson IPO 30 million shares were issued, accounting for 15% of the issued share capital, and the issue price per share was $24. After the IPO raised $720 million, the total number of shares of Mead Johnson increased to 200 million shares. The company's market value was $4.8 billion based on the issue price per share of $24. Bristol Myers Squibb will hold 83% equity after listing. -
In 2010, Bristol Myers Squibb acquired ZymoGenetics -
In 2011, Bristol Myers Squibb acquired Amira Pharmaceuticals -
In 2012, BMS acquired Inhibitex Inc -
In 2012, Bristol Myers Squibb acquired AstraZeneca Amylin Pharmaceuticals -
In 2014, Bristol Myers Squibb acquired iPierian -
In 2015, Bristol Myers Squibb acquired Flexus Biosciences -
In 2015, Bristol Myers Squibb acquired Cardioxy -
In 2016, Bristol Myers Squibb acquired Padlock Therapeutics -
In 2016, Bristol Myers Squibb acquired Cormorant Pharmaceuticals -
In 2017, Bristol Myers Squibb acquired IFM Therapeutics -
On January 3, 2019, Bristol Myers Squibb announced that it would purchase a total of 74 billion dollars in cash and stock New based medicine (Selgene). The original shareholders of Celgene can obtain one share of Bristol Myers Squibb plus $50 in cash for each share and the expected value right (CVR) of $9 in cash in the future. By acquiring Celgene, BMS can acquire several product line assets with blockbuster potential in the fields of tumor, immunity and inflammation, including TYK2, ozanimod, luspatercept, liso cel (JCAR017), bb2121, federanib, etc. The acquisition was completed on November 20 of the same year. -
In 2020, Bristol Myers Squibb also acquired Forbius and MyoKardia. -
On October 21, 2021, according to Bloomberg, Acceleron Pharma BMY, the largest shareholder of XLRN, plans to bid for its shares in XLRN. The transaction will help promote Merck (MRK)'s plan to acquire Acceleron for US $11.5B. Bristol Myers Squibb holds 11.5% of Acceleron shares. -
On June 3, 2022, Bristol Myers Squibb (BMY) and Turning Point Therapeutics, Inc. (TPTX) announced today a final merger agreement under which Bristol Myers Squibb will acquire Turning Point Therapeutics at a price of US $76.00 per share. The transaction was unanimously approved by the Board of Directors of Bristol Myers Squibb and Turning Point Therapeutics, and was finally completed in August 2022. -
In August 2023, Bristol Myers Squibb cooperated with Cellares to produce CAR-T therapy by robot, and has obtained two approvals. -
In September 2023, BMS announced that it would prepay US $50 million to Zenas BioPharma to obtain strategic license and cooperation to develop and commercialize obexelimab, a new bifunctional antibody for the treatment of autoimmune diseases. -
In October 2023, BMS agreed to purchase with a full cash transaction worth $4.8 billion and an additional milestone payment of $1 billion Mirati Therapeutics This is an American company that develops targeted cancer therapy Biotechnology Company 。 The transaction was completed in January 2024. -
On December 22, 2023, Bristol Myers Squibb (NYSE: BMY) announced that it would acquire the company for 14B dollars Karuna Therapeutics (KRTX) 。 The transaction will be completed in March 2024. -
On December 26, 2023, Bristol Myers Squibb (BMY) and RayzeBio, Inc. (RYZB) announced that it had reached a final merger agreement, according to which Bristol Myers Squibb would acquire RayzeBio in cash at $62.50 per share, with a total equity value of about $4.1 billion. The transaction will be completed in February 2024.
Bristol Myers Squibb (BMY) US equity investment
| | | | |
|---|---|---|---|
| | | | |
| | | | |
| | | | |
